Yearly Archives: 2025

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance regarding the transition to the new formulation and risk of medication error with Rybelsus® tablets. There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus® tablets, which have different stated mg [...]

The post MHRA Drug Safety Update: Rybelsus® (semaglutide tablets): transition to new formulation and risk of medication error appeared first on Community Pharmacy England.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance regarding the transition to the new formulation and risk of medication error with Rybelsus® tablets. There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus® tablets, which have different stated mg [...]

The post MHRA Drug Safety Update: Rybelsus® (semaglutide tablets): transition to new formulation and risk of medication error appeared first on Community Pharmacy England.

The Department of Health and Social Care has announced that The Human Medicines (Authorisation by Pharmacists and Supervision by Pharmacy Technicians) Order 2025 has been approved by Parliament and the Privy Council, and will come into force in two stages. The order makes changes to The Medicines Act 1968 and The Human Medicines Regulations 2012 [...]

The post Pharmacy supervision legislation to come into force in 2026 appeared first on Community Pharmacy England.

Summary: New joint service specification for COVID-19 and adult flu vaccinations published. COVID-19 vaccinations become an Advanced service. Fees for both vaccinations uplifted, but additional fee for housebound patients removed. Pharmacy owners must use the National Booking Service (NBS) for COVID-19 vaccinations, but this is still not a requirement for flu. Registration for spring COVID-19 [...]

The post C-19 & Adult Flu vac: joint 2026/27 service spec published, with fee uplifts from April 2026 appeared first on Community Pharmacy England.

MHRA Class 3 Medicines Recall: Prednisolone 5mg Soluble Tablets (Activase Pharmaceuticals Limited) Drug Alert Number: EL(25)A/54 Date issued: 15 December 2025 Activase Pharmaceuticals Limited is recalling two batches of Prednisolone 5mg Soluble Tablets as a precautionary measure due to a limited number of reports of blister pockets becoming swollen over time. DMRC reference number: DMRC – 37820855 [...]

The post MHRA Class 3 Medicines Recall: Prednisolone 5mg Soluble Tablets (Activase Pharmaceuticals Limited) appeared first on Community Pharmacy England.